Evidence map›Paper›PMID 39861864›Full record

ArticleViruses2025

Structural Analysis of Inhibitor Binding to Enterovirus-D68 3C Protease.

Vincent N Azzolino, Ala M Shaqra, Akbar Ali, Nese Kurt Yilmaz, Celia A Schiffer

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vincent N AzzolinoDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0003-3186-4760
Ala M ShaqraDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Akbar AliDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0003-3491-791X
Nese Kurt YilmazDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-5036-676X
Celia A SchifferDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0003-2270-6613

Funding

Defining and Avoiding Molecular Mechanisms of Drug ResistanceR35GM151996 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Celia A. Schiffer · 2024 to 2026
$1.5M
Characterization of Enterovirus 68 3C Protease For the Development of Robust and Potent Direct-Acting Antiviral InhibitorsF30AI181515 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Vincent Azzolino · 2024 to 2026
$167k
NIAID NIH HHS F30 AI181515NIGMS NIH HHS R35 GM151996NIH HHS 1F30AI181515-01A1NIH HHS 1R35GM151996-01A1
6 · The paper itself

Abstract

Enterovirus-D68 (EV68) continues to present as a global health issue causing respiratory illness and outbreaks associated with long-lasting neurological disease, with no antivirals or specific treatment options. The development of antiviral therapeutics, such as small-molecule inhibitors that target conserved proteins like the enteroviral 3C protease, remains to be achieved. While various 3C inhibitors have been investigated, their design does not consider the potential emergence of drug resistance mutations. For other antivirals where resistance has been a challenge, we have demonstrated that the likelihood of resistance can be minimized by designing inhibitors that leverage the evolutionary constraints of the target. Here, we characterize a series of 3C inhibitors against EV68-3C protease through enzyme inhibition, protein crystallography, and structural analysis. We have determined and analyzed three high-resolution inhibitor-bound crystal structures of EV68-3C protease, which revealed possible sites of resistance mutations, a key structural water molecule conserved during ligand binding, and the conformational flexibility of the catalytic histidine H40. This structural analysis combined with enzymatic assays provides insights for the rational design of inhibitors that are robust against resistance toward developing antiviral treatments for EV68 infections.

Indexed as

Antiviral AgentsCysteine EndopeptidasesEnterovirus D, HumanViral Protease InhibitorsViral Proteins3C Viral ProteasesCrystallography, X-RayDrug Resistance, ViralEnterovirus InfectionsHumansModels, MolecularMutationProtein BindingProtein Conformation3C Viral ProteasesAntiviral AgentsCysteine EndopeptidasesViral Protease InhibitorsViral Proteinsdrug resistanceenterovirusEV68inhibition assaysproteaseprotein structure

Identifiers

PMID39861864
PMCPMC11768739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.